DelveInsight’s “Dry Eye Disease Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in the Dry Eye Disease pipeline landscape. It covers the Dry Eye
DelveInsight’s “Plaque Psoriasis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Plaque Psoriasis pipeline landscape. It covers the Plaque Psoriasis pipeline drug
DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease Pipeline Insight 2026” report provides comprehensive insights about 13+ companies and 14+ pipeline drugs in the Autosomal Dominant Polycystic Kidney Disease pipeline landscape. It
DelveInsight’s, “Tenosynovial Giant Cell Tumors Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tenosynovial Giant Cell Tumors pipeline landscape. It covers the Tenosynovial
DelveInsight’s, “Myasthenia Gravis Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis Pipeline drug profiles,
Stuart Piltch Scholarship for Entrepreneurs Stuart Piltch Champions Next Generation of Business Builders with New Undergraduate Scholarship for Aspiring Entrepreneurs NEW YORK, NY – The Stuart Piltch Scholarship for Entrepreneurs today
Non-Alcoholic Steatohepatitis Clinical Trial Key Non-Alcoholic Steatohepatitis (NASH) Companies include Novo Nordisk, Viking Therapeutics, Inventiva Pharma, GlaxoSmithKline, Haisco Pharmaceutical Group, and others The Non-Alcoholic Steatohepatitis (NASH) therapeutic landscape is entering
STAT Inhibitors Clinical Trials Key STAT Inhibitors Companies include Tvardi Therapeutics, Kymera Therapeutics, Recludix Pharma, Enanta Pharmaceuticals, Moleculin, Purple Biotech, LEO Pharma, JW Pharmaceutical, KAKEN PHARMACEUTICAL, C4XD Holdings, and others
Dr. Andrew Hummel Launches Distinguished Scholarship Initiative to Advance Future Medical Science Leaders and Aspiring Physicians Dr. Andrew Hummel Launches Distinguished Scholarship Initiative to Advance Future Medical Science Leaders and
Diabetic Neuropathy Clinical Trial Leading diabetic neuropathy companies include Vertex Pharmaceuticals Incorporated, Novaremed, Trevena, Inc., WinSanTor, Inc., AlgoTherapeutix, Tris Pharma, Inc., JMackem Co., Ltd, Lexicon Pharmaceuticals, Merz Pharmaceuticals GmbH, and
